BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Black SW, Morairty SR, Chen TM, Leung AK, Wisor JP, Yamanaka A, Kilduff TS. GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy. J Neurosci 2014;34:6485-94. [PMID: 24806675 DOI: 10.1523/JNEUROSCI.0080-14.2014] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Tisdale RK, Yamanaka A, Kilduff TS. Animal models of narcolepsy and the hypocretin/orexin system: Past, present, and future. Sleep 2021;44:zsaa278. [PMID: 33313880 DOI: 10.1093/sleep/zsaa278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Szabo ST, Thorpy MJ, Mayer G, Peever JH, Kilduff TS. Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy. Sleep Med Rev 2019;43:23-36. [PMID: 30503715 DOI: 10.1016/j.smrv.2018.09.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
3 Peyron C, Kilduff TS. Mapping the Hypocretin/Orexin Neuronal System: An Unexpectedly Productive Journey. J Neurosci 2017;37:2268-72. [PMID: 28250055 DOI: 10.1523/JNEUROSCI.1708-16.2016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 3.6] [Reference Citation Analysis]
4 Rempe MJ, Clegern WC, Wisor JP. An automated sleep-state classification algorithm for quantifying sleep timing and sleep-dependent dynamics of electroencephalographic and cerebral metabolic parameters. Nat Sci Sleep 2015;7:85-99. [PMID: 26366107 DOI: 10.2147/NSS.S84548] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
5 Zou B, Cao WS, Guan Z, Xiao K, Pascual C, Xie J, Zhang J, Xie J, Kayser F, Lindsley CW, Weaver CD, Fang J, Xie XS. Direct activation of G-protein-gated inward rectifying K+ channels promotes nonrapid eye movement sleep. Sleep 2019;42:zsy244. [PMID: 30535004 DOI: 10.1093/sleep/zsy244] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
6 Tabuchi S, Tsunematsu T, Black SW, Tominaga M, Maruyama M, Takagi K, Minokoshi Y, Sakurai T, Kilduff TS, Yamanaka A. Conditional ablation of orexin/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function. J Neurosci 2014;34:6495-509. [PMID: 24806676 DOI: 10.1523/JNEUROSCI.0073-14.2014] [Cited by in Crossref: 116] [Cited by in F6Publishing: 64] [Article Influence: 14.5] [Reference Citation Analysis]
7 Wozniak DR, Quinnell TG. Unmet needs of patients with narcolepsy: perspectives on emerging treatment options. Nat Sci Sleep 2015;7:51-61. [PMID: 26045680 DOI: 10.2147/NSS.S56077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
8 Bhattarai J, Sumerall S. Current and Future Treatment Options for Narcolepsy: A Review. Sleep Sci 2017;10:19-27. [PMID: 28966734 DOI: 10.5935/1984-0063.20170004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
9 Mahoney CE, Agostinelli LJ, Brooks JN, Lowell BB, Scammell TE. GABAergic Neurons of the Central Amygdala Promote Cataplexy. J Neurosci 2017;37:3995-4006. [PMID: 28235898 DOI: 10.1523/JNEUROSCI.4065-15.2017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
10 Abad VC, Guilleminault C. New developments in the management of narcolepsy. Nat Sci Sleep 2017;9:39-57. [PMID: 28424564 DOI: 10.2147/NSS.S103467] [Cited by in Crossref: 47] [Cited by in F6Publishing: 13] [Article Influence: 9.4] [Reference Citation Analysis]
11 Toossi H, Del Cid-Pellitero E, Jones BE. GABA Receptors on Orexin and Melanin-Concentrating Hormone Neurons Are Differentially Homeostatically Regulated Following Sleep Deprivation. eNeuro 2016;3:ENEURO. [PMID: 27294196 DOI: 10.1523/ENEURO.0077-16.2016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
12 Irukayama-Tomobe Y, Ogawa Y, Tominaga H, Ishikawa Y, Hosokawa N, Ambai S, Kawabe Y, Uchida S, Nakajima R, Saitoh T, Kanda T, Vogt K, Sakurai T, Nagase H, Yanagisawa M. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. Proc Natl Acad Sci U S A 2017;114:5731-6. [PMID: 28507129 DOI: 10.1073/pnas.1700499114] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 10.6] [Reference Citation Analysis]
13 Lee EK, Douglass AB. Baclofen for narcolepsy with cataplexy: two cases. Nat Sci Sleep 2015;7:81-3. [PMID: 26251634 DOI: 10.2147/NSS.S86649] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
14 Seifinejad A, Vassalli A, Tafti M. Neurobiology of cataplexy. Sleep Med Rev 2021;60:101546. [PMID: 34607185 DOI: 10.1016/j.smrv.2021.101546] [Reference Citation Analysis]
15 Williams RH, Black SW, Thomas AM, Piquet J, Cauli B, Kilduff TS. Excitation of Cortical nNOS/NK1R Neurons by Hypocretin 1 is Independent of Sleep Homeostasis. Cereb Cortex 2019;29:1090-108. [PMID: 29462275 DOI: 10.1093/cercor/bhy015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
16 Black SW, Schwartz MD, Chen TM, Hoener MC, Kilduff TS. Trace Amine-Associated Receptor 1 Agonists as Narcolepsy Therapeutics. Biol Psychiatry 2017;82:623-33. [PMID: 27919403 DOI: 10.1016/j.biopsych.2016.10.012] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
17 Venzi M, Di Giovanni G, Crunelli V. A critical evaluation of the gamma-hydroxybutyrate (GHB) model of absence seizures. CNS Neurosci Ther 2015;21:123-40. [PMID: 25403866 DOI: 10.1111/cns.12337] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
18 Williams RH, Tsunematsu T, Thomas AM, Bogyo K, Yamanaka A, Kilduff TS. Transgenic Archaerhodopsin-3 Expression in Hypocretin/Orexin Neurons Engenders Cellular Dysfunction and Features of Type 2 Narcolepsy. J Neurosci 2019;39:9435-52. [PMID: 31628177 DOI: 10.1523/JNEUROSCI.0311-19.2019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
19 Swick TJ. Treatment paradigms for cataplexy in narcolepsy: past, present, and future. Nat Sci Sleep 2015;7:159-69. [PMID: 26715865 DOI: 10.2147/NSS.S92140] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
20 Black SW, Yamanaka A, Kilduff TS. Challenges in the development of therapeutics for narcolepsy. Prog Neurobiol 2017;152:89-113. [PMID: 26721620 DOI: 10.1016/j.pneurobio.2015.12.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
21 Pérez-carbonell L. Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy. Curr Treat Options Neurol 2019;21. [DOI: 10.1007/s11940-019-0595-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]